When ef­fi­ca­cy is bor­der­line: FDA needs to get more con­sis­tent on close-call drug ap­provals, agency-fund­ed re­search finds

In the ex­ceed­ing­ly rare in­stances in which clin­i­cal ef­fi­ca­cy is the on­ly bar­ri­er to a new drug’s ap­proval, new FDA-fund­ed re­search from FDA and Stan­ford …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.